Latest Beta amyloid Stories
A study funded in part by the Cure Alzheimer's Fund looking at the links between cholesterol and Alzheimer's brings researchers closer to identifying a drug to interrupt the disease process.
Though one might think the brains of people who develop Alzheimer's disease (AD) possess building blocks of the disease absent in healthy brains, for most sufferers, this is not true.
UCLA chemists and molecular biologists have for the first time used a "structure-based" approach to drug design to identify compounds with the potential to delay or treat Alzheimer's disease, and possibly Parkinson's, Lou Gehrig's disease and other degenerative disorders.
Researchers at Columbia University Medical Center recently discovered key molecular pathways in the brain that lead to late-onset Alzheimer's disease, the most common form of the disorder.
- Growing in low tufty patches.